Overview


According to FutureWise analysis the market for angina pectoris therapeutics in 2023 is US$ 10.06 billion, and is expected to reach US$ 15.7 billion by 2031 at a CAGR of 5.70%.

Angina pectoris, or stable angina, is a medical term for discomfort or chest pain due to coronary artery disease. It occurs when the heart muscles don’t get the sufficient amount of blood that is needed. This usually happens when one or more heart arteries are narrowed or blocked, also called ischemia. It increases during a physical activity like climbing a hill or stairs. Furthermore, Emotional stress, exposure to scorching and cold temperatures, heavy meals, and smoking are possible triggers for angina pectoris. It may also occur when you are in a rest state. 

People with stable angina have chest pain episodes that usually last for a short time (5 min or less). The pain may also radiate to the other region, like the arms, back, or other areas. It may occur in both males and females. Patients often complain of pressure, tightness, heaviness, or burning in the locations in addition to the chest, including the shoulder, arm, neck, upper abdomen, or jaw. There are different types of anginas, such as STABLE ANGINA which is the most common angina and happens during exertion and goes away with rest or medication; UNSTABLE ANGIAN is a medical emergency that is unpredictable and occurs at rest, and it is typically severe and last longer than stable angina, it does not go away with rest or medication and is also dangerous and requires emergency treatments; VARIANT ANGINA is caused by a spasm in the heart’s arteries that temporarily reduces blood flow, severe chest pain is the most common symptom of this, and it can be relieved by medications; REFRACTORY ANGINA in which angina episodes are frequent despite a combination of drugs and lifestyle changes.

FutureWise Market Research has published a report that provides an insightful analysis of Angina Pectoris Therapeutics Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Angina Pectoris Therapeutics Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Amgen Inc.
  • Pfizer Inc.
  • Johnson and Johnson
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Abbott
  • Bayer AG
  • Orion Corporation
  • MerckCo. Inc.
  • Cardiorentis AG.

(Note: The list of the major players will be updated with the latest market scenario and trends)

The Angina pectoris therapeutic market is a rapidly expanding industry that has seen tremendous growth in recent years. The expansion of this market has been driven by the rising surge in the patient pool suffering from cardiac disorders. The demand for Angina pectoris therapeutic has expanded partly due to the increased incidence of chronic illnesses and the aging population. For instance, in December 2022, ischaemic heart disease was the world’s leading cause of death, accounting for 16% of all deaths according to the data given by WHO. The development of new technologies and products with applications in medicine is one of the key factors driving the market for angina pectoris therapeutic. The demand for Angina pectoris therapeutic is also gaining from rising R&D expenditures by both public and commercial companies. As private businesses invest in new technologies to gain a competitive advantage, governments fund angina pectoris therapeutic market research to enhance healthcare delivery and save healthcare expenses.

However, the market for Angina pectoris therapeutics also confronts several difficulties. These are some of the expenses of Angina pectoris therapeutics, regulatory barriers, and a lack of standard procedures for manufacturing and using Angina pectoris therapeutics. 

By Type of Angina

  • Stable angina
  • Unstable angina
  • Prinzmetal's angina

By Drug Class

  • Nitrates
  • Non-steroidal anti-inflammatory drugs
  • Anti-platelet drugs
  • Beta blockers
  • Statins
  • Calcium antagonists
  • Angiotensin-converting enzyme (ACE) inhibitors
  • Others

By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • E-pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. Due to the established healthcare infrastructure, increased therapeutics adoption, and key manufacturers' presence in the United States, North America has accounted for the largest share in the market. Coronary heart disease is a significant cause of death and disability occurring within the North American region. According to the National Center for Chronic Disease Prevention and Health Promotion's Division for Heart Disease and Stroke Prevention, in February 2022, ischemic heart disease was the most common type of heart disease and caused 360,900 deaths in 2019. Roughly 20% of deaths caused by coronary artery disease occur in adults under the age of 65.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Angina Pectoris Therapeutics Market By Type of Angina, By Drug Class, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Angina Pectoris Therapeutics Market Variables, Trends and Scope
    •   1. Market LineProducts Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Angina Pectoris Therapeutics Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Angina Pectoris Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Angina Pectoris Therapeutics Market, By Type of Angina Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Stable angina
        2. Unstable angina
        3. Prinzmetal's angina

  • 8.   Angina Pectoris Therapeutics Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Nitrates
        2. Non-steroidal anti-inflammatory drugs
        3. Anti-platelet drugs
        4. Beta blockers
        5. Statins
        6. Calcium antagonists
        7. Angiotensin-converting enzyme (ACE) inhibitors
        8. Others

  • 9.   Angina Pectoris Therapeutics Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital pharmacy
        2. Retail pharmacy
        3. E-pharmacy

  • 10.   North America Angina Pectoris Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Angina Pectoris Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Angina Pectoris Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Angina Pectoris Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Amgen Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Pfizer Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Johnson and Johnson
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Novartis AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bristol-Myers Squibb Company
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Abbott
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bayer AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Orion Corporation
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. MerckCo. Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Cardiorentis AG.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients